Last Price$8.511.2%
Market Cap$1,347.5M
LTM EBIT to Interest coverage
(12.7x)
5Y avg
(10.5x)
Biotechnology industry
median
(31.1x)
Stock quality & Intrinsic value
6/10
0.1% undervalued
Ocular Therapeutix, Inc. EBIT to Interest coverage
Annual
Quarterly
LTM
Industry median
Company stand-alone
Crunching data... Almost there!
| Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EBIT to Interest coverage | (36.3x) | (29.3x) | (24.2x) | (22.2x) | (25.8x) | (32.7x) | (34.0x) | (14.1x) | (9.3x) | (11.7x) | (11.2x) | (7.3x) | (12.7x) |
Overvalued or undervalued?
Check the intrinsic value for OCUL
and see if it's the right time to invest.
Ocular Therapeutix, Inc. (OCUL) EBIT to Interest coverage comparison analysis
General
LTM EBIT to Interest coverage
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
Ocular Therapeutix, Inc.OCUL
(12.7x)
9.0%
11.9%
(303.7%)
Median Peer Set
(0.6x)
14.8%
(19.3%)
7.5%
Regeneron Pharmaceuticals, Inc.REGN
72.9x
8.3%
10.4%
31.1%
BioMarin Pharmaceutical Inc.BMRN
37.3x
18.0%
139.3%
15.0%
United Therapeutics CorporationUTHR
32.1x
23.6%
25.7%
41.5%
Royalty Pharma plcRPRX
5.7x
(3.8%)
(43.7%)
37.9%
Alnylam Pharmaceuticals, Inc.ALNY
(1.2x)
23.0%
(38.6%)
(12.4%)
Vertex Pharmaceuticals IncorporatedVRTX
(8.1x)
11.7%
N/A
(4.9%)
Summit Therapeutics Inc.SMMT
(24.3x)
N/A
(68.7%)
N/A
BioNTech SEBNTX
(65.7x)
(77.4%)
(89.7%)
24.4%
argenx SEARGX
(189.1x)
198.6%
(60.5%)
(24.1%)
BeiGene, Ltd.BGNE
N/A
73.7%
467.1%
(35.9%)
OCUL key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 0.0 0.0% | 0.0 (100.0%) | 0.8 0.0% | 1.8 126.7% | 1.9 7.8% | 1.9 1.9% | 2.0 3.5% | 4.2 112.4% | 17.4 311.7% | 43.5 150.1% | 51.5 18.3% | 58.4 13.5% | 63.7 9.0% |
| Cost of Goods Sold (COGS) | 0.0 | 10.5 | 0.1 | 0.3 | 0.4 | 0.5 | 0.5 | 2.3 | 2.1 | 4.4 | 4.5 | 5.3 | 5.6 |
% margin | 0.0 30.0% | (10.5) 0.0% | 0.7 88.2% | 1.4 81.8% | 1.4 76.5% | 1.5 76.2% | 1.5 76.6% | 1.9 45.0% | 15.3 88.0% | 39.1 89.9% | 47.0 91.2% | 53.2 91.0% | 58.1 91.2% |
| Operating Expenses | 13.7 | 12.9 | 27.8 | 39.6 | 44.8 | 63.4 | 60.6 | 87.7 | 78.2 | 117.2 | 125.6 | 135.5 | 229.9 |
| Research & Development Expenses (R&D) | 11.5 | 10.5 | 18.9 | 26.6 | 27.1 | 30.9 | 36.9 | 41.1 | 28.7 | 50.1 | 53.5 | 61.1 | 127.6 |
| Selling, General & Administrative Expenses (SG&A) | 2.1 | 2.4 | 8.9 | 13.0 | 17.7 | 32.5 | 23.7 | 46.6 | 49.5 | 67.1 | 72.1 | 74.5 | 102.2 |
% margin | (13.7) (136,710.0%) | (12.9) 0.0% | (27.1) (3,509.6%) | (38.2) (2,182.7%) | (43.3) (2,296.0%) | (61.9) (3,220.1%) | (59.1) (2,970.8%) | (85.8) (2,029.9%) | (62.8) (361.1%) | (78.0) (179.3%) | (78.7) (152.7%) | (82.4) (141.0%) | (171.8) (269.6%) |
| Interest Income | 0.0 | 0.0 | 0.0 | 0.2 | 0.3 | 0.4 | 0.9 | 1.2 | 0.2 | 0.0 | 0.8 | 4.0 | 20.3 |
| Interest Expense | 0.4 | 0.4 | 1.1 | 1.7 | 1.7 | 1.9 | 1.7 | 6.1 | 6.8 | 6.7 | 7.0 | 11.3 | 13.6 |
| Pre-tax Income | (14.1) | (13.3) | (28.6) | (39.7) | (44.7) | (63.4) | (60.0) | (86.4) | (155.6) | (6.6) | (71.0) | (80.7) | (193.5) |
% effective tax rate | 0.3 (2.3%) | 0.5 (3.4%) | 0.1 (0.5%) | 1.0 (2.5%) | 0.8 (1.8%) | 0.3 (0.4%) | (2.3) 3.8% | 3.6 (4.1%) | 4.0 (2.6%) | 4.3 (64.9%) | (7.6) 10.7% | 0.0 0.0% | 0.0 0.0% |
% margin | (14.1) (140,930.0%) | (13.3) 0.0% | (28.6) (3,710.9%) | (39.7) (2,271.3%) | (44.7) (2,369.0%) | (63.4) (3,296.2%) | (57.7) (2,899.1%) | (89.9) (2,127.6%) | (159.6) (917.3%) | (10.8) (24.8%) | (63.4) (123.2%) | (80.7) (138.1%) | (193.5) (303.7%) |
| EPS | (4.77) | (4.51) | (2.69) | (1.71) | (1.80) | (2.20) | (1.51) | (1.99) | (2.63) | (0.14) | (0.83) | (1.09) | (1.22) |
| Diluted EPS | (4.77) | (4.51) | (2.69) | (1.71) | (1.80) | (2.20) | (1.51) | (1.99) | (2.63) | (0.13) | (0.83) | (1.02) | (1.22) |
% margin | (13.3) (133,120.0%) | (12.5) 0.0% | (27.0) (3,495.1%) | (37.3) (2,129.7%) | (42.1) (2,233.3%) | (59.9) (3,113.3%) | (56.0) (2,811.7%) | (77.7) (1,839.2%) | (146.1) (839.5%) | (75.6) (173.7%) | (61.9) (120.2%) | (66.4) (113.6%) | (176.1) (276.4%) |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Ocular Therapeutix, Inc.'s EBIT to Interest coverage?
As of today, Microsoft Corp's last 12-month EBIT to Interest coverage is (12.7x), based on the financial report for Dec 31, 2024 (Q4’2024). The average annual EBIT to Interest coverage for Ocular Therapeutix, Inc. have been (10.3x) over the past three years, and (11.1x) over the past five years.
2) Is Ocular Therapeutix, Inc.'s EBIT to Interest coverage Good?
As of today, Ocular Therapeutix, Inc.'s EBIT to Interest coverage is (12.7x), which is higher than industry median of (31.1x). It indicates that Ocular Therapeutix, Inc.'s EBIT to Interest coverage is Good.